Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2003

Study Completion Date

March 31, 2007

Conditions

Age-Related Macular Degenerations.Subfoveal Neovascularization.

Interventions

DRUG

Anecortave Acetate

Trial Locations (1)

Manhattan Eye, Ear & Throat Hospital, New York